Arcus Biosciences (RCUS) Payables (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Payables of $39.0 million for Q1 2026, up 77.27% year-over-year from $22.0 million in Q1 2025, and down 7.14% quarter-over-quarter from $42.0 million in Q4 2025.
Arcus Biosciences (RCUS) Payables (2017 - 2026) Analysis & Trends
Arcus Biosciences' Payables history runs 10 years deep, the most recent figure standing at $39.0 million for Q1 2026.
- In Q1 2026, Payables rose 77.27% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $39.0 million (up 77.27% YoY), while the FY2025 annual figure was $42.0 million, up 133.33% from the prior year.
- Payables for Q1 2026 stood at $39.0 million, down from $42.0 million in the prior quarter.
- The five-year high for Payables was $42.0 million in Q3 2025, with the low at $10.5 million in Q3 2022.
- The 5-year median for Payables is $18.1 million (2022), against an average of $22.4 million.
- The sharpest annual moves came in 2023 and 2025: Payables tumbled 45.41% in 2023, then surged 223.08% in 2025.
- Arcus Biosciences' Payables stood at $20.0 million in 2022, then fell by 15.0% to $17.0 million in 2023, then advanced by 5.88% to $18.0 million in 2024, then soared by 133.33% to $42.0 million in 2025, then retreated by 7.14% to $39.0 million in 2026.
- Business Quant data shows RCUS's Payables at $39.0 million in Q1 2026, $42.0 million in Q4 2025, and $42.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 34.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.00 Mn |
| Mar 31, 2026 | 39.00 Mn |
| Dec 31, 2025 | 42.00 Mn |
| Sep 30, 2025 | 42.00 Mn |
| Jun 30, 2025 | 29.00 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Dec 31, 2024 | 18.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 16.00 Mn |
| Dec 31, 2023 | 17.00 Mn |
| Sep 30, 2023 | 17.00 Mn |
| Jun 30, 2023 | 12.00 Mn |
| Mar 31, 2023 | 28.00 Mn |
| Dec 31, 2022 | 20.00 Mn |
| Sep 30, 2022 | 10.55 Mn |
| Jun 30, 2022 | 21.98 Mn |
| Mar 31, 2022 | 18.09 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 13.22 Mn |